SLC25A46 Antibody

What is SLC25A46 and why is it important for mitochondrial research?

SLC25A46 belongs to the SLC25 family of mitochondrial carrier proteins and functions as an integral outer membrane protein that localizes to mitochondrial fusion and fission sites. This protein has gained significant research attention because loss of its function alters mitochondrial morphology and is associated with a spectrum of neurodegenerative diseases . SLC25A46 is found at discrete puncta at mitochondrial branch points and tips of mitochondrial tubules, where it co-localizes with key proteins involved in mitochondrial dynamics such as DRP1 and OPA1 . Virtually all mitochondrial fission and fusion events are demarcated by an SLC25A46 focus, making it a crucial protein for maintaining proper mitochondrial network architecture and function.

What are the key specifications of commercially available SLC25A46 antibodies?

SLC25A46 antibodies such as the 12277-1-AP are polyclonal antibodies typically raised in rabbit hosts. These antibodies target specific regions of the SLC25A46 protein and can detect the protein in multiple species including human, mouse, and rat samples. The antibody recognizes SLC25A46 with an observed molecular weight of approximately 46 kDa, which aligns with the calculated molecular weight based on its 418 amino acid sequence . The antibody is generally supplied in liquid form in PBS buffer with sodium azide and glycerol for stability, and should be stored at -20°C where it remains stable for approximately one year after shipment .

What applications are SLC25A46 antibodies validated for?

SLC25A46 antibodies have been validated for several experimental applications:

Additionally, these antibodies have been extensively cited in peer-reviewed publications for use in knockdown/knockout validation studies . For optimal results, researchers should titrate the antibody in their specific testing system as sensitivity can be sample-dependent.

How should SLC25A46 antibody be optimized for Western blot analysis of mitochondrial fractions?

For optimal Western blot results when analyzing mitochondrial fractions, begin with purifying mitochondria using differential centrifugation or commercial mitochondrial isolation kits. Since SLC25A46 is a mitochondrial outer membrane protein, ensure that during fractionation the outer membrane remains intact. A standard protocol involves:

• Lysing cells in appropriate buffer (RIPA or NP-40-based)

• Loading 20-40 μg of mitochondrial protein per lane

• Using 10-12% polyacrylamide gels for optimal separation

• Starting with a 1:1000 dilution of SLC25A46 antibody and adjusting based on signal intensity

• Including appropriate positive controls (Jurkat cells, mouse/rat brain tissue have shown consistent detection)

For challenging samples, consider longer exposure times during detection. Western blot analysis has been crucial in studies comparing SLC25A46 protein levels in wild-type versus pathogenic variants, where researchers observed that disease severity inversely correlates with the steady-state levels of SLC25A46 protein .

What controls are necessary when using SLC25A46 antibody in immunofluorescence studies of mitochondrial morphology?

When conducting immunofluorescence studies of mitochondrial morphology using SLC25A46 antibody, implement these essential controls:

• Positive Control: Include samples known to express SLC25A46 (e.g., Jurkat cells or normal fibroblasts)

• Negative Control: Use an SLC25A46 knockout cell line (CRISPR/Cas9-generated lines have been established in fibroblasts and HeLa cells)

• Mitochondrial Co-localization: Co-stain with established mitochondrial markers (MitoTracker or antibodies against other mitochondrial proteins like TOM20)

• Antibody Specificity Control: Include secondary antibody-only controls

• Morphology Comparison Control: Include cells with known mitochondrial morphologies (fragmented vs. hyperfused networks)

Research has shown that complete loss of SLC25A46 in knockout cells results in marked fragmentation of the mitochondrial network, while cells expressing pathogenic variants exhibit extensive mitochondrial hyperfusion . These distinct morphological phenotypes serve as excellent internal controls for validating immunofluorescence results.

How can SLC25A46 antibody be used to investigate protein-protein interactions in the mitochondrial fusion/fission machinery?

SLC25A46 antibody is valuable for investigating protein-protein interactions within the mitochondrial dynamics machinery through several advanced techniques:

• Co-immunoprecipitation (Co-IP): Endogenous SLC25A46 can be immunoprecipitated using validated antibodies, followed by immunoblotting for interaction partners. Research has demonstrated that SLC25A46 co-immunoprecipitates with critical fusion machinery components including MFN1, MFN2, and OPA1, as well as the MICOS complex component MIC25 . This approach requires:

  • Optimization of lysis conditions to preserve membrane protein interactions

  • Careful antibody selection to avoid interference with protein interaction domains

  • Appropriate controls including IgG-only immunoprecipitation

• Proximity Labeling: Analysis of protein proximity interaction networks has identified SLC25A46 interactions with both mitochondrial fusion and fission machinery, as well as proteins involved in intracellular vesicular transport . This technique provides spatial context for protein interactions.

• Super-resolution Microscopy: Using fluorescently labeled SLC25A46 antibody alongside antibodies against potential interaction partners (DRP1, OPA1) allows visualization of co-localization at fusion/fission sites at nanoscale resolution.

These approaches have been instrumental in characterizing SLC25A46 as a critical component that interacts with both fusion and fission machinery components, positioning it as a potential regulator of the balance between these processes.

What approaches can resolve contradictory findings regarding SLC25A46 knockdown/knockout effects on mitochondrial morphology?

The literature contains apparently contradictory findings regarding the effect of SLC25A46 loss on mitochondrial morphology, with some studies reporting fragmentation and others reporting hyperfusion. To resolve these contradictions, consider these methodological approaches:

• Compare Acute vs. Chronic Loss Models: Research has shown different outcomes between acute siRNA-mediated knockdown (reported hyperfusion) versus CRISPR/Cas9-induced knockout (reported fragmentation) . Design experiments that:

  • Compare both approaches in the same cell line

  • Include time-course analysis after inducible knockout

  • Quantify morphology using standardized parameters (length, branching, area)

• Assess Cell Type Specificity: Different cell types may compensate differently for SLC25A46 loss. Test the same perturbation across:

  • Cell lines (fibroblasts, HeLa, neuronal cell lines)

  • Primary cells

  • Cells derived from different tissues in knockout animal models

• Evaluate Expression of Compensatory Proteins: Measure levels of other mitochondrial dynamics proteins (MFN1/2, OPA1, DRP1) following SLC25A46 manipulation to identify potential compensatory mechanisms.

• Consider Residual Protein Function: For pathogenic variants, assess remaining protein levels, as disease severity inversely correlates with steady-state SLC25A46 levels , suggesting pathogenic variants are hypomorphic rather than complete loss-of-function.

These approaches can help reconcile seemingly contradictory findings and provide a more complete understanding of SLC25A46's role in mitochondrial dynamics.

What are the optimal approaches for generating SLC25A46 knockout/knockdown cellular models?

Researchers have successfully employed multiple strategies to generate SLC25A46-deficient cellular models:

• CRISPR/Cas9 Gene Editing:

  • Successfully used to generate complete SLC25A46 knockout in both fibroblasts and HeLa cells

  • Enables stable, complete loss of protein expression

  • Allows for rescue experiments by re-introducing wild-type or mutant constructs

  • Permits clonal selection for population homogeneity

• siRNA/shRNA Knockdown:

  • Provides acute, transient reduction in protein levels

  • Useful for examining immediate consequences of protein depletion

  • May produce different phenotypes compared to complete knockout

  • Offers flexibility in targeting different regions of the transcript

• Expression of Pathogenic Variants:

  • Stable cell lines expressing SLC25A46 pathogenic variants (p.T142I, p.R257Q, p.E335D) have been established

  • Allows comparative analysis across variants with different clinical severities

  • Enables structure-function relationship studies

When designing these models, consider including appropriate controls such as non-targeting gRNAs/siRNAs and rescue experiments with wild-type SLC25A46 to confirm phenotype specificity. Studies have shown that knockout cells display proliferation defects that can be rescued by wild-type SLC25A46 expression but not by pathogenic variants , highlighting the importance of rescue experiments.

What animal models are available for studying SLC25A46 function, and how can they be characterized?

Several animal models have been developed to study SLC25A46 function:

• Mouse Models:

  • TALEN-generated knockout models have been established in pure FVB/N genetic background

  • Two characterized transgenic lines:

    • Tg26 line with 75 bp deletion causing exon 3 aberrant splicing

    • Tg18 line with 15 bp insertion/3 bp deletion affecting transmembrane domain

  • Both lines show undetectable SLC25A46 protein by western blot analysis

• Bovine Model:

  • Naturally occurring SLC25A46 mutation identified in cattle with hereditary syndrome

  • Single nucleotide substitution in SLC25A46 gene

For characterization of these models, comprehensive approaches should include:

• Molecular Validation:

  • Western blot analysis of tissue samples for protein expression

  • RT-PCR for transcript analysis (reveals alternative splicing, nonsense-mediated decay)

  • Sequencing to confirm genetic modifications

• Physiological Assessment:

  • Growth curves and viability monitoring

  • Neurological phenotyping (relevant due to association with neurodegenerative diseases)

  • Metabolic analysis

• Cellular/Subcellular Analysis:

  • Electron microscopy for mitochondrial ultrastructure (particularly cristae morphology)

  • Analysis of mitochondrial network in primary cells derived from model animals

  • Assessment of mitochondrial function (respiration, membrane potential)

These models are invaluable for understanding SLC25A46 function in vivo and investigating tissue-specific effects of its deficiency.

How can SLC25A46 antibodies help characterize patient-derived samples with mitochondrial disorders?

SLC25A46 antibodies serve as crucial tools for characterizing patient-derived samples in cases of suspected mitochondrial disorders:

• Diagnostic Application:

  • Western blot analysis can identify reduced SLC25A46 protein levels in patient fibroblasts or muscle biopsies

  • Research has established a correlation between residual protein levels and disease severity

  • Immunofluorescence can reveal altered mitochondrial morphology (typically hyperfusion in patient cells)

• Variant Characterization Protocol:

  • Establish primary fibroblast cultures from patient skin biopsies

  • Perform western blot analysis with 1:1000 antibody dilution to quantify protein levels

  • Conduct immunofluorescence using both SLC25A46 antibody and mitochondrial markers

  • Compare results with healthy controls and known pathogenic variants

  • Correlate findings with clinical severity

• Mechanistic Investigation:

  • Co-immunoprecipitation to assess how mutations affect interaction with fusion/fission partners

  • Analysis of OPA1 oligomerization state, which is altered with loss of SLC25A46 function

  • Examination of MFN2 oligomerization patterns

This approach has successfully differentiated various pathogenic variants (p.T142I, p.R257Q, p.E335D) in terms of their effects on protein stability and mitochondrial morphology, confirming that disease-causing variants act as hypomorphs rather than complete loss-of-function mutations .

What techniques can determine if novel SLC25A46 variants affect protein stability versus functional interactions?

Distinguishing between protein stability defects and functional interaction defects for novel SLC25A46 variants requires a multi-faceted approach:

• Protein Stability Assessment:

  • Cycloheximide Chase Assay: Treat cells expressing variant protein with cycloheximide to block new protein synthesis, then collect samples at time intervals for western blot analysis to determine protein half-life

  • Proteasome Inhibition: Treatment with MG132 or other proteasome inhibitors can reveal if variants are subject to enhanced proteasomal degradation

  • Thermal Shift Assay: Assess protein thermal stability in vitro using purified recombinant proteins

• Functional Interaction Analysis:

  • Co-immunoprecipitation: Compare wild-type and variant SLC25A46 ability to pull down known interaction partners (MFN1, MFN2, OPA1, MIC25)

  • Proximity Ligation Assay: Visualize and quantify protein-protein interactions in situ

  • Rescue Experiments: Test if variant can rescue mitochondrial morphology and proliferation defects in SLC25A46 knockout cells

• Integrated Analysis:

  • Compare results with known pathogenic variants spanning different stability levels

  • Correlate findings with structural predictions based on the variant location

  • Assess effects on OPA1 and MFN2 oligomerization, which are downstream indicators of functional impact

This methodological framework successfully characterized three known pathogenic variants (p.T142I, p.R257Q, and p.E335D), revealing that although all showed reduced stability, their differential effects on mitochondrial dynamics corresponded to their clinical severity .

What strategies can overcome common technical challenges when using SLC25A46 antibody for immunofluorescence?

Researchers often encounter technical difficulties when using SLC25A46 antibody for immunofluorescence. Here are evidence-based solutions:

• Low Signal Intensity:

  • Optimize antibody concentration (start with 1:200-1:500 and adjust)

  • Extend primary antibody incubation to overnight at 4°C

  • Use signal amplification systems (tyramide signal amplification or more sensitive detection systems)

  • Ensure antigen retrieval is adequate for fixed samples (citrate buffer pH 6.0, heat-mediated)

• High Background:

  • Increase blocking time (minimum 1 hour with 5% BSA or 10% normal serum)

  • Add 0.1-0.3% Triton X-100 in blocking and antibody solutions

  • Include 0.05% Tween-20 in wash buffers

  • Ensure secondary antibody is highly cross-adsorbed

• Detecting Endogenous Levels:

  • Use confocal microscopy with appropriate settings for detecting low abundance proteins

  • Consider SLC25A46's localization pattern to mitochondrial branch points and tips when evaluating specific signal

  • Include mitochondrial co-staining for confirming specific localization

  • Use knockout cells as negative controls for signal validation

• Preserving Mitochondrial Morphology:

  • Fix cells with 4% paraformaldehyde for 10-15 minutes (avoid methanol fixation)

  • Perform mild permeabilization (0.1% Triton X-100 for 5 minutes)

  • Consider live cell imaging with fluorescently tagged SLC25A46 for dynamic studies

  • Process samples quickly to avoid artifacts in mitochondrial network structure

These approaches have enabled researchers to successfully visualize SLC25A46 at discrete puncta at mitochondrial branch points and tips, co-localizing with mitochondrial dynamics proteins like DRP1 and OPA1 .

What is the optimal protocol for quantifying changes in SLC25A46 protein levels in response to experimental manipulations?

An optimized protocol for reliable quantification of SLC25A46 protein levels includes:

• Sample Preparation:

  • Extract proteins using RIPA or NP-40 buffer supplemented with protease inhibitors

  • For mitochondrial enrichment, use differential centrifugation (12,000g pellet)

  • Include phosphatase inhibitors if phosphorylation status is relevant

  • Determine protein concentration using BCA or Bradford assay

• Western Blot Optimization:

  • Load 20-40 μg total protein per lane (adjust based on expression level)

  • Use 10-12% SDS-PAGE for optimal separation around 46 kDa

  • Transfer to PVDF membrane (preferred over nitrocellulose for mitochondrial proteins)

  • Block with 5% non-fat milk in TBST for 1 hour at room temperature

  • Incubate with SLC25A46 antibody at 1:1000 dilution overnight at 4°C

  • Use appropriate HRP-conjugated secondary antibody (1:5000-1:10000)

• Quantification Strategy:

  • Include loading control (VDAC1 or TOM20 for mitochondrial fraction, β-actin or GAPDH for total lysate)

  • Use at least three biological replicates per condition

  • Measure band intensity using ImageJ or similar software

  • Normalize SLC25A46 signal to loading control

  • For time-course experiments, normalize to time zero or control condition

• Validation Approaches:

  • Include positive control (wild-type cells) and negative control (knockout cells)

  • For subtle changes, consider using a standard curve of recombinant protein

  • Confirm protein level changes with mRNA analysis (qRT-PCR)

This protocol has successfully quantified differences in steady-state SLC25A46 levels between wild-type and pathogenic variants, revealing an inverse correlation between protein levels and disease severity , and enabling comparison between different experimental models.